Curriculum Update #4
• Bradykinin and angiotensin-(1-7): Emerging allies in vascular function
The role of endothelial function in cardiovascular health provides an important conceptual framework for development of risk reduction strategies. This slide program, part of a continuing series of educational activities, is produced under the auspices of the Vascular Biology Working Group (VBWG) and covers new aspects of the renin-angiotensin system (RAS) that have implications for vascular function.
This program discusses new data on the interaction between the RAS and the kallikrein-kinin system (KKS), as well as intriguing new research on the novel RAS peptide angiotensin-(1-7). These data extend our understanding of ACE inhibition at the tissue level and its role in reducing the risk of cardiovascular morbidity and mortality.
Advances in our understanding of the kallikrein-kinin system (KKS) and the renin-angiotensin system (RAS) have led to new insights into the mechanism of action of angiotensin-converting enzyme (ACE) inhibitors.
In particular, this Curriculum Update covers the following topics:
- Beneficial cardiovascular effects of bradykinin
- Receptors and pathways of the RAS and the KKS
- Relative roles of ACE, angiotensin-(1-7), and angiotensin II (Ang II) in maintenance of blood pressure and endothelial function
- Evidence that bradykinin is an important mediator of the cardiovascular effects of tissue ACE inhibition
- Importance of tissue ACE inhibition in cardiovascular risk reduction
Published by Medical Education Consultants, Inc. (MEDCON), on behalf of the University of Florida College of Medicine. Supported by an unrestricted educational grant from Pfizer Inc.
The editorial content of this program expresses the views of the individual contributors and does not necessarily reflect the views or recommendations of the University of Florida College of Medicine, Pfizer Inc, or the publisher. The indications and dosages of drugs discussed in this program may vary from those approved by the Food and Drug Administration (FDA). The reader is advised to consult the full prescribing information for each medication prior to use.
Bradykinin and angiotensin-(1-7): Emerging allies in vascular function
Download CU4.ppt (23 slides - 1.1MB)